Microcap Ledger Nkarta, Inc. $NKTX
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Global Select Market
- Sector
- Pharmaceutical Preparations
- Headquarters
- South San Francisco, CA
- Fiscal year end
- December 31
- Shares outstanding
- 71,624,791 [10-Q 2026-08-10]
What the company doesAI summary of filing
Nkarta, Inc. is a clinical-stage biopharmaceutical company developing allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The company's lead program is NKX019, a CAR NK cell therapy targeting CD19 for treatment of autoimmune diseases, currently in Phase 1 clinical trials for lupus nephritis, primary membranous nephropathy, systemic sclerosis, myositis, and ANCA-associated vasculitis, as well as investigator-sponsored trials for systemic lupus erythematosus and myasthenia gravis. Nkarta has not generated revenue from product sales and is a pre-revenue, clinical-stage company that makes money through research and development activities funded by capital; the company operates internal cGMP manufacturing facilities in South San Francisco to produce clinical supply and plans for potential future commercial production. [10-K 2026-03-25]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | — | −$68.20M | −$52.42M | $24.96M | [10-Q 2026-08-10] |
| FY ended Dec 2025 | $0.00 | −$104.08M | −$88.70M | $39.63M | [10-K 2026-03-25] |
| FY ended Dec 2024 | $0.00 | −$108.79M | −$99.70M | $27.87M | [10-K 2025-03-26] |
- Quarterly cash burn
- −$26.21M
- Cash runway Estimate
- ~2.9 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-04 | 70,568,754 | [10-Q 2024-11-07] |
| 2025-03-21 | 70,957,554 | [10-K 2025-03-26] |
| 2025-05-09 | 70,957,554 | [10-Q 2025-05-14] |
| 2025-08-08 | 71,024,512 | [10-Q 2025-08-12] |
| 2025-11-05 | 71,029,512 | [10-Q 2025-11-10] |
| 2026-03-18 | 71,290,490 | [10-K 2026-03-25] |
| 2026-05-07 | 71,545,358 | [10-Q 2026-05-12] |
| 2026-08-05 | 71,624,791 | [10-Q 2026-08-10] |
- Shelf registration
- S-3 filed 2026-03-25; declared effective 2026-04-03 [S-3 2026-03-25]
Listing status
Current status: No Form 8-K Item 3.01 (listing notice) filings in the last 24 months, as of 2026-10-11.
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-06-18 | Hastings Paul J | sell | 1,776 | $2.71 | [4 2026-06-22] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-08-10 | 10-Q | Quarterly report |
| 2026-08-10 | 8-K | Results of operations |
| 2026-06-11 | 8-K | Shareholder vote results |
| 2026-05-19 | 13D/A | Beneficial ownership report (5%+ holder) |
| 2026-05-12 | 10-Q | Quarterly report |
| 2026-05-12 | 8-K | Results of operations |
| 2026-04-23 | DEF 14A | Proxy statement |
| 2026-04-03 | 424B5 | Prospectus or prospectus supplement |
| 2026-03-26 | 8-K | Other events |
| 2026-03-25 | S-3 | Registration statement |
| 2026-03-25 | 10-K | Annual report |
| 2026-03-25 | 8-K | Results of operations |
Alerts for $NKTX
Email me when Nkarta, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.